CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation’s Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing. The new studies show that siRNAs designed to target a virus known to infect CHO cells - cells that are commonly used to produce recombinant proteins and monoclonal antibodies - can potently block infection and viral replication. RNAi technologies to prevent or treat viral infection of manufacturing cell lines could provide a novel strategy to ensure product quality of biotherapeutic products for patients.
